A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas-Reference-Cited by-同舟云学术

A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas

Published:2017-12-26 Issue:12 Volume:9 Page:2695-2716
ISSN:1945-4589
Container-title:Aging
language:en
Short-container-title:Aging

Author:

Hadjadj Djihad¹,Kim Su-Jung¹,Denecker Thomas¹,Ben Driss Laura¹,Cadoret Jean-Charles¹,Maric Chrystelle¹,Baldacci Giuseppe¹,Fauchereau Fabien¹²

Affiliation:

1. Pathologies de la Réplication de l'ADN, Université Paris-Diderot – Paris 7, Sorbonne Paris Cité, CNRS UMR7592, Institut Jacques-Monod, 75205 Paris Cedex 13, France

2. ePôle de Génoinformatique, Université Paris-Diderot – Paris 7, Sorbonne Paris Cité, CNRS UMR7592, Institut Jacques-Monod, 75205 Paris Cedex 13, France

Publisher

Impact Journals, LLC

Subject

Cell Biology,Ageing

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Wnt/β-catenin signaling pathway in the tumor progression of adrenocortical carcinoma;Frontiers in Endocrinology;2024-01-09

2. Advances in translational research of the rare cancer type adrenocortical carcinoma;Nature Reviews Cancer;2023-10-19

3. Firing of Replication Origins Is Disturbed by a CDK4/6 Inhibitor in a pRb-Independent Manner;International Journal of Molecular Sciences;2023-06-25

4. Wnt Signaling Pathway Collapse upon β-Catenin Destruction by a Novel Antimicrobial Peptide SKACP003: Unveiling the Molecular Mechanism and Genetic Activities Using Breast Cancer Cell Lines;Molecules;2023-01-17

5. Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art?;Expert Opinion on Pharmacotherapy;2022-08-03